Ontario-based Intellijoint Surgical has announced the approval of the CE Mark (Conformité Européenne) for its intellijoint HIP System in Europe. As noted in the company’s October 4, 2017 news release, “A 3D Mini-Optical Navigation System, intellijoint HIP provides surgeons with precise measurements for cup position, leg length and offset for Total Hip Arthroplasty (THA). Requiring no pre-operative or intra-operative imaging, the system can be used with any implant manufacturer.”
Intellijoint Surgical: CE Mark for Hip System

“The intellijoint HIP is available for both an anterior approach as well as lateral and posterior approaches, regardless of incision size. The 3D Mini-Optical tracking by Intellijoint is the only one of its kind and serves as the core technology for THA’s and other orthopedic surgical applications in development.”
“The CE mark supports our mission of making the intellijoint HIP technology accessible to every surgeon and every patient,” explained Intellijoint CEO Armen Bakirtzian. “Intellijoint Surgical has developed a global strategy for its product portfolio and our rapid expansion in the US market paired with our versatile business model has prepared us for global scale.”
Bakirtzian told OTW, “ intellijoint HIP was conceived by three engineering students at the University of Waterloo and now the novel miniature 3D navigation technology is approved for use across North America and Europe. Intellijoint plans to enter the European market in 2018 while leveraging its CE Mark for Australian expansion in late 2017.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.